P Eshghi
Overview
Explore the profile of P Eshghi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarihi R, Ahmadnejad M, Mohammadi S, Eshghi P, Herfat F, Jolharnejad S, et al.
Transfus Apher Sci
. 2020 Sep;
60(1):102913.
PMID: 32943324
Anti-Hr (Anti-Rh17) is a rare immune Immunoglobulin G (IgG) to high-frequency Rh antigens that may cause severe and often fatal Hemolytic disease of the fetus and newborn (HDFN) in D--,...
2.
Kavakli K, Demartis F, Karimi M, Eshghi P, Neme D, Chambost H, et al.
Haemophilia
. 2017 Apr;
23(4):575-582.
PMID: 28440004
Introduction: A room temperature stable formulation of recombinant activated factor VII (NovoSeven ), allowing convenient storage and therefore improved treatment access, has been developed. Bioequivalence to the previous NovoSeven was...
3.
Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, et al.
Clin Appl Thromb Hemost
. 2014 Oct;
22(2):184-90.
PMID: 25343955
Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episodes in patients with hemophilia A with inhibitors. Methods: Sixty-six patients were randomized into 2 groups, with...
4.
Faranoush M, Abolghasemi H, Toogeh G, Karimi M, Eshghi P, Managhchi M, et al.
Clin Appl Thromb Hemost
. 2014 Mar;
21(8):724-8.
PMID: 24651301
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 μg/kg, intravenously...
5.
Naderi M, Dorgalaleh A, Tabibian S, Alizadeh S, Eshghi P, Solaimani G
Iran J Ped Hematol Oncol
. 2014 Feb;
3(4):164-72.
PMID: 24575291
Factor XIII or "fibrin-stabilizing factor," is a transglutaminase circulates in the blood circulation as a hetero tetramer with two catalytic A subunits and two carrier B subunits. This important coagulation...
6.
Eshghi P, Jenabzade A, Habibpanah B
Hematology
. 2013 Oct;
19(6):361-4.
PMID: 24164872
Objective: The aim of this study was to assess the effectiveness of localized treatments to persistently stop epistaxis in patients with inherited bleeding disorders. Methods: In a self-controlled comparative clinical...
7.
Alzoebie A, Belhani M, Eshghi P, Kupesiz A, Ozelo M, Pompa M, et al.
Haemophilia
. 2013 Apr;
19(5):668-73.
PMID: 23590670
Over recent decades tremendous progress has been made in diagnosing and treating haemophilia and, in resource-rich countries, life expectancy of people with haemophilia (PWH) is now close to that of...
8.
Naderi M, Eshghi P, Cohan N, Haghpanah S, Karimi M
Haemophilia
. 2013 Mar;
19(3):e175-6.
PMID: 23510337
No abstract available.
9.
Naderi M, Eshghi P, Saneei Moghaddam E, Alizadeh S, Dorgalaleh A, Younesi M, et al.
Haemophilia
. 2012 Dec;
19(2):e90-2.
PMID: 23216799
No abstract available.
10.
Dental health and oral health-related quality of life in children with congenital bleeding disorders
Salem K, Eshghi P
Haemophilia
. 2012 Sep;
19(1):65-70.
PMID: 22970656
The purpose of this study was to investigate the dental and some other aspects of oral health status of young patients with congenital bleeding disorders (CBD) and the impact of...